AI Rating
6.5
Key Drivers
- Higher rebounds
- Resistance test
- Volatile reversal
AIAI Summary
6.5
ODTX has shifted from a near-term financing risk to a cash-backed clinical platform with runway into 2028, so the investment case now hinges on whether OD-001 can convert its early ulcerative colitis proof-of-concept into repeatable efficacy and pipeline re-rating rather than on survival, with execution failure the main downside risk.
ClinicalCatalyst
ExecutionRisk
CashRunway
Price Chart
Loading chart...
Financial Metrics
-
Revenue (TTM)-
Net Income (TTM)-
EPS (Q)-
MCAPDeep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
0.0
Price Behavior
6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.
Key Price Behavior Insights:
- •Higher rebounds
- •Resistance test
- •Volatile reversal
ODTX has rebounded strongly over the last month and is now testing $18.7-$18.9 resistance, but it still needs a decisive breakout to confirm the bullish recovery.
bullish
watchlist
Support Level: $17.6-$17.7
Resistance Level: $18.7-$18.9
Sharp drop into
Sentiment & News
0.0
Similar Companies in Healthcare
Other companies in the same sector with AI ratings
NBIX
Neurocrine Biosciences, Inc.
8.0
Fundamental8.5
Technical6.5
Sentiment8.0
EHC
Encompass Health Corporation
8.0
Fundamental8.0
Technical7.0
Sentiment7.0
KRYS
Krystal Biotech, Inc.
8.0
Fundamental9.0
Technical6.0
Sentiment7.0
A
Agilent Technologies, Inc.
8.0
Fundamental8.0
Technical6.0
Sentiment8.0
WST
West Pharmaceutical Services, Inc.
7.6
Fundamental8.6
Technical6.4
Sentiment7.4